Queen Mary Hospital
Hong Kong
Location status: Recruiting
NCT Number: NCT07416149
This is a prospective, single-blinded, randomized controlled trial to evaluate whether PTeye™ can reduce post-operative hypoparathyroidism (PH). The study will enroll consecutive patients undergoing total thyroidectomy in a teritary endocrine surgery unit in Hong Kong, randomizing them into receiving conventional surgery versus PTeye™-assisted surgery. Subjects will be assigned to the two groups before surgery. Subjects will be under medical care as in usual practice.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Hong Kong
Location status: Recruiting
Post-operative hypoparathyroidism (PH) is a debilitating complication following total thyroidectomy. It arises from inadvertent removal or devascularization of the parathyroid glands. From a previous study in Hong Kong and other population-wide series, permanent PH rates could be as high as 11%, and transient PH rates being 30-48%, posing substantial burden on healthcare systems.
Near-infrared autofluorescence (NIRAF) technology has emerged to assist the identification and preservation of parathyroid glands during surgery. This study investigates the probe-based NIRAF device, PTeye™, which emits laser and receives NIR real-time, thereby detecting parathyroid glands by a simple touch of a probe.
A standardized protocol is devised to use PTeye™ for parathyroid identification at the early stage of surgery, in order to avoid devascularization or inadvertent removal of the parathyroids.
This is a prospective, single-blinded, randomized controlled trial to evaluate whether PTeye™ can reduce PH. The study will enroll consecutive patients undergoing total thyroidectomy in a tertiary endocrine surgery unit in Hong Kong. Patients will be randomized to receive conventional surgery or PTeye™-assisted surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The PTeye™ parathyroid detection system is an adjunctive tool to aid in the identification of visually suspected parathyroid tissue as granted by DEN17005.
Time frame: 6 months
Rate of significant post-operative hypoparathyroidism (SPH) after total thyroidectomy (in %)
Time frame: within 4 weeks from operation
Rate of inadvertent parathyroidectomy (in %)
Time frame: within operation
Rate of parathyroid auto-transplantation (in %)
Time frame: Post-operative Day 0
Day 0 Post-operative serum parathyroid hormone levels (pmol/L)
Time frame: Post-operative Day 1
Day 1 Post-operative serum parathyroid hormone levels (pmol/L)
Time frame: Post-operative 3 months
3-month Post-operative serum parathyroid hormone levels (pmol/L)
Time frame: Post-operative 6 months
6-month Post-operative serum parathyroid hormone levels
Contact information is provided by the study sponsor or research team.
The University of Hong Kong
Other
Reducing Post-operative Hypoparathyroidism With Probe-based Near Infrared Autofluorescence (NIRAF)- Assisted Total Thyroidectomy Versus Conventional Total Thyroidectomy, a Randomized-controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07428057
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Minya, Minya Governorate, Egypt
View Trial DetailsNCT05732883
Calcium Metabolism Disorders, Cranial Nerve Diseases
Hong Kong
View Trial DetailsNCT07617584
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Skopje, North Macedonia
View Trial DetailsNCT00743782
Autoimmune Diseases, Autoimmune Polyendocrine Syndrome Type 1
Bethesda, Maryland, United States
View Trial Details